title: Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
abstract: CMX001 is an orally available lipid acyclic nucleotide phosphonate that delivers high intracellular levels of cidofovir (CDV)-diphosphate and exhibits enhanced in vitro antiviral activity against a wide range of double-stranded DNA viruses, including cytomegalovirus (CMV). Mutations in the DNA polymerase of CMV that impart resistance to CDV also render the virus resistant to CMX001. Here, we report a novel resistance mutation that arose under the selective pressure of CMX001. The wild-type CMV strain AD169 was propagated in human foreskin fibroblasts under increasing concentrations of CMX001 over 10 months, and the resulting strain (named CMX001(R)) was less susceptible to CDV and CMX001 in a plaque reduction assay. Genotypic analysis of virus strain CMX001(R) via conventional sequencing of the genes encoding the CMV DNA polymerase (UL54) and UL97 kinase (UL97) demonstrated one mutation that changed the wild-type aspartate to glutamate at position 542 in UL54. A recombinant virus with this novel D542E mutation was generated via bacterial artificial chromosome-mediated marker transfer experiments. Subsequent phenotypic resistance analysis of the D542E mutant demonstrated reductions in susceptibility of greater than 10-fold to CMX001 and CDV, but no resistance to foscarnet (FOS) or ganciclovir (GCV). Analysis of replicative fitness showed that both strain CMX001(R) and the D542E mutant viruses demonstrated a smaller plaque phenotype and slower replication kinetics than their respective parent viruses. These data describe the first resistance mutation generated under the selective pressure of CMX001 and suggest that CMX001 may have a unique resistance profile associated with reduced viral replication and maintenance of sensitivity to FOS and GCV.
authors: University of Alabama at Birmingham, Birmingham, Alabama, USA.
authors: Scott H
authors: SH
authors: James
authors: Nathan B
authors: NB
authors: Price
authors: Caroll B
authors: CB
authors: Hartline
authors: E Randall
authors: ER
authors: Lanier
authors: Mark N
authors: MN
authors: Prichard
mesh_terms: D000595:Amino Acid Sequence; D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D002478:Cells, Cultured; D022202:Chromosomes, Artificial, Bacterial; D000077404:Cidofovir; D003587:Cytomegalovirus / Q000187:drug effects* / Q000235:genetics; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000821:virology; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004259:DNA-Directed DNA Polymerase / Q000737:chemistry / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics*; D017245:Foscarnet / Q000494:pharmacology; D015774:Ganciclovir / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000494:pharmacology*; D010641:Phenotype; D017422:Sequence Analysis, DNA
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D017245:Foscarnet; C525733:brincidofovir; D003596:Cytosine; D004259:DNA-Directed DNA Polymerase; D000077404:Cidofovir; D015774:Ganciclovir
references: Antimicrob Agents Chemother. 2005 Sep;49(9):3724-33
references: 16127046
references: Rev Med Virol. 2007 Sep-Oct;17(5):355-63
references: 17542052
references: Virology. 1998 Sep 1;248(2):382-93
references: 9721246
references: Clin Infect Dis. 2008 Sep 1;47(5):702-11
references: 18652557
references: J Virol. 1999 Jul;73(7):5663-70
references: 10364316
references: Mol Pharmacol. 2003 Mar;63(3):678-81
references: 12606777
references: J Virol. 2008 May;82(10):5054-67
references: 18321963
references: Cancer Immunol Immunother. 2009 Sep;58(9):1481-8
references: 19466407
references: Antimicrob Agents Chemother. 2007 Nov;51(11):4160-2
references: 17709468
references: Herpes. 2007 Dec;14(3):66-71
references: 18371289
references: Curr Opin Virol. 2011 Dec;1(6):548-54
references: 22162744
references: Infect Disord Drug Targets. 2009 Apr;9(2):201-22
references: 19275707
references: J Antimicrob Chemother. 2003 Sep;52(3):319-23
references: 12917233
references: Antimicrob Agents Chemother. 2012 May;56(5):2726-34
references: 22391537
references: J Infect Dis. 2004 Aug 1;190(3):499-503
references: 15243923
references: Antimicrob Agents Chemother. 2002 Aug;46(8):2381-6
references: 12121908
references: Clin Microbiol Rev. 2010 Oct;23(4):689-712
references: 20930070
references: Biochem Pharmacol. 1996 Jun 14;51(11):1563-7
references: 8630098
references: Proteins. 2006 Aug 1;64(2):301-7
references: 16705640
references: Antiviral Res. 2003 Aug;59(3):163-71
references: 12927306
references: J Infect Dis. 2003 Jul 1;188(1):32-9
references: 12825168
references: Antiviral Res. 2009 May;82(2):A84-98
references: 19425198
references: Antimicrob Agents Chemother. 1997 Mar;41(3):594-9
references: 9055999
references: Antimicrob Agents Chemother. 2005 Feb;49(2):656-62
references: 15673748
references: Virus Res. 2011 May;157(2):212-21
references: 21095209
references: Infect Disord Drug Targets. 2011 Oct;11(5):504-13
references: 21827431
references: Antimicrob Agents Chemother. 2004 Sep;48(9):3516-22
references: 15328119